Machine signal
Active cluster sell — 5 distinct insiders, $22.7M, window ends Sep 25, 2026.
Figures computed from official regulatory filings — .
Analysttarget 198.69 USD (+21%) · consensus 4.64/5 · 13 buy · 1 hold · 0 sell
Ownershipinsiders 3.58% · institutions 105.08% · short 8.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for GLAUKOS Corp only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
5 buys410 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Navratil Tomas | Sell | $167.7K | SEC |
| Navratil Tomas | Sell | $35.3K | SEC |
| Navratil Tomas | Sell | $20.8K | SEC |
| Navratil Tomas | Sell | $25.3K | SEC |
| Navratil Tomas | Sell | $56.8K | SEC |
| Navratil Tomas | Sell | $20.2K | SEC |
| Navratil Tomas | Sell | $688 | SEC |
| Navratil Tomas | Sell | $16.8K | SEC |
| Navratil Tomas | Sell | $77K | SEC |
| Navratil Tomas | Sell | $40K | SEC |
| Navratil Tomas | Sell | $31.7K | SEC |
| Navratil Tomas | Sell | $1.4M | Unusual size | SEC |
| Navratil Tomas | Sell | $1.1M | Unusual size | SEC |
| Navratil Tomas | Sell | $1.8K | SEC |
| Kliman Gilbert Htrack record | Exercise | $64.4K | SEC |
| Kliman Gilbert Htrack record | Sell | $475K | SEC |
| Kliman Gilbert Htrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gilliam Joseph E | Exercise | $484.6K | Unusual size | SEC |
| Gilliam Joseph E | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gilliam Joseph E | Exercise | $1.1M | Unusual size | SEC |
| Gilliam Joseph E | Exercise | $1.1M | Unusual size | SEC |
| Gilliam Joseph E | Exercise | $484.6K | Unusual size | SEC |
| Gilliam Joseph E | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gilliam Joseph E | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gilliam Joseph E | Sell | $5.8M | Unusual size | SEC |